Back to MRK Stock Lookup

Merck & Co., Inc. (MRK) – Company Press Releases

Apr 24, 2014 07:41 AM Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Apr 23, 2014 08:00 AM Merck and Award-Winning Actress S. Epatha Merkerson Challenge Americans with Type 2 Diabetes to Get to Their Goals
Apr 23, 2014 07:35 AM Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Apr 17, 2014 06:22 PM FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in
Apr 14, 2014 05:59 PM FDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children a
Apr 11, 2014 01:00 AM Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
Apr 10, 2014 01:00 AM Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection
Apr 7, 2014 02:20 AM EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
Apr 6, 2014 10:30 AM Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck’s Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014
Apr 4, 2014 08:00 AM Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth
Apr 1, 2014 08:00 AM EMD Serono, Inc. Launches 10th Edition of The EMD Serono Specialty Digest™ at Annual Meeting of The Academy of Managed Care Pharmacy
Apr 1, 2014 07:00 AM EMD Serono Enters into Research Agreement with Pfizer and Broad Institute
Mar 27, 2014 07:20 AM Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007
Mar 24, 2014 07:30 AM Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress™ 2014
Mar 21, 2014 08:05 AM Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients
Mar 20, 2014 05:00 PM Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29
Mar 17, 2014 01:55 PM EMD Millipore Announces Clinical Research, Licensing and Joint Development Agreement with Sysmex Corporation
Mar 14, 2014 01:40 PM FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for Intravenous Use
Mar 10, 2014 03:18 PM EMD Millipore Receives Grant from Massachusetts Life Sciences Center to Collaborate with Promethera Biosciences
Mar 5, 2014 04:15 PM Merck’s Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection
Mar 5, 2014 12:15 PM Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults
Mar 5, 2014 12:15 PM New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
Mar 4, 2014 05:45 PM ALK's partner in North America, Merck, presents data on investigational house dust mite sublingual allergy immunotherapy tablet
Mar 4, 2014 05:30 PM Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
Feb 28, 2014 08:30 AM CHMP Issues Positive Opinion for Tablet Formulation of Merck’s NOXAFIL® (posaconazole)
Feb 25, 2014 12:31 PM Merck Announces Second-Quarter 2014 Dividend
Feb 20, 2014 05:00 PM Merck to Participate in the Citi 2014 Healthcare Conference
Feb 20, 2014 08:30 AM FDA Accepts for Review Merck’s Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine
Feb 17, 2014 03:00 AM MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner)
Feb 13, 2014 08:30 AM EMD Serono Strengthens Leadership With New Appointments
Feb 10, 2014 08:30 AM Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes
Feb 5, 2014 07:00 AM Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results
Feb 5, 2014 06:40 AM Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475
Feb 3, 2014 08:30 AM Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)

Back to MRK Stock Lookup